Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane
Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane O'Shaughnessy, J., Schwartzberg, L., Piccart, M., Rugo, H. S., Yardley, D. A., Cortes, J., Untch, M., Harbeck, N., Wright, G. S., Bondarenko, I., Glaspy, J., Nowecki, Z., Kayali, F., Chan, A., Levy, C., Liu, M., Kim, S., Lemieux, J., Manikhas, A., Tolaney, S., Lim, E., Gombos, A., Stradella, A., Pegram, M., Fasching, P., Mangel, L., Semiglazov, V., Dieras, V., Gianni, L., Danso, M. A., Vacirca, J., Kroll, S., O'Connell, J., Tang, K., Wei, T., Seidman, A. AMER ASSOC CANCER RESEARCH. 2021View details for Web of Science ID 000618737700023